Praxis Medical Insights

Medication-Induced Leukopenia

Cytotoxic chemotherapy is the most common iatrogenic cause of leukopenia, with dose-dependent myelosuppression occurring predictably after treatment 1
Azathioprine and cyclophosphamide should be stopped or reduced by 50% if WBC drops below 4,000/mm³ or platelets fall below 100,000/mm³, with weekly monitoring until recovery 2
Clozapine carries significant risk of agranulocytosis and requires extensive monitoring protocols, including baseline WBC ≥3,500/mm³ before initiating therapy, weekly blood counts for first 6 months, then biweekly thereafter 3, 4
Immediate discontinuation of clozapine is required if WBC drops below 2,000/mm³ or absolute neutrophil count (ANC) below 1,000/mm³ 3
Medications like carbamazepine with bone marrow suppression potential should be avoided when using agents like clozapine 3, 4

Acute promyelocytic leukemia (APL) often presents with low WBC counts (≤10 × 10⁹/L) at diagnosis, and patients with low WBC at presentation may delay chemotherapy until genetic confirmation, though ATRA should be started immediately upon suspicion 5

WBC <2,000/mm³ or ANC <1,000/mm³ requires immediate medication discontinuation and daily monitoring for infection 3, 4
Febrile neutropenia represents a medical emergency requiring blood cultures before antibiotics and infectious disease consultation 6
Patients on chemotherapy or immunosuppressants require regular CBC monitoring, with frequency based on agent and risk profile 1, 2
Avoid invasive procedures (central lines, lumbar puncture, bronchoscopy) during active neutropenia due to hemorrhagic complications 5

Do not continue myelosuppressive medications when WBC drops below critical thresholds without dose adjustment 2
Do not delay ATRA in suspected APL while awaiting genetic confirmation if clinical suspicion is high 5
Concurrent medications that lower blood counts should be identified and avoided when possible 3, 4